ValuEngine Downgrades Pfizer (NYSE:PFE) to Sell

ValuEngine cut shares of Pfizer (NYSE:PFE) from a hold rating to a sell rating in a research note issued to investors on Thursday morning, ValuEngine reports.

A number of other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. lowered their price target on Pfizer from $37.00 to $36.00 and set a neutral rating for the company in a report on Monday, June 1st. Royal Bank of Canada reiterated a buy rating and set a $43.00 price target on shares of Pfizer in a report on Monday, July 20th. TheStreet upgraded Pfizer from a c+ rating to a b rating in a report on Monday, June 1st. Zacks Investment Research cut shares of Pfizer from a buy rating to a hold rating and set a $40.00 price target on the stock. in a research report on Monday, May 4th. Finally, SVB Leerink lifted their price objective on shares of Pfizer from $39.00 to $42.00 and gave the company a market perform rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. Pfizer has a consensus rating of Hold and a consensus target price of $38.95.

NYSE PFE traded down $0.26 during mid-day trading on Thursday, hitting $38.48. The stock had a trading volume of 27,042,691 shares, compared to its average volume of 32,108,124. The firm’s 50 day moving average is $34.75 and its 200 day moving average is $35.79. Pfizer has a twelve month low of $27.88 and a twelve month high of $40.97. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78. The stock has a market capitalization of $213.75 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 3.10 and a beta of 0.68.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The company had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a return on equity of 25.10% and a net margin of 28.80%. The firm’s quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.80 EPS. As a group, equities research analysts expect that Pfizer will post 2.9 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 31st will be issued a $0.38 dividend. The ex-dividend date of this dividend is Thursday, July 30th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.95%. Pfizer’s dividend payout ratio is presently 51.53%.

In other news, SVP Jennifer B. Damico sold 2,181 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $36.13, for a total value of $78,799.53. Following the completion of the transaction, the senior vice president now owns 7,542 shares in the company, valued at approximately $272,492.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.08% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Corbett Road Capital Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at approximately $25,000. New England Investment & Retirement Group Inc. purchased a new position in shares of Pfizer during the 1st quarter worth $26,000. Lion Street Advisors LLC purchased a new position in shares of Pfizer during the 1st quarter worth $27,000. Reitz Capital Advisors LLC purchased a new position in shares of Pfizer during the 2nd quarter worth $29,000. Finally, Benjamin Edwards Inc. lifted its stake in shares of Pfizer by 49.8% during the 1st quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 335 shares during the period. 70.20% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Are sell-side analysts objective?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.